PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway
Article in Cell Death & Disease (April 2024)
The most recent citing publications are shown below. View all 74 publications that cite this research output on Dimensions.
Article in Cell Death & Disease (April 2024)
Article in Journal of Clinical Investigation (March 2023)
Article in Frontiers in Endocrinology (August 2022)